Dynavax Technologies Corporation (DVAX) Downgraded to “Hold” at BidaskClub

BidaskClub cut shares of Dynavax Technologies Corporation (NASDAQ:DVAX) from a buy rating to a hold rating in a research report report published on Monday, July 31st.

Other equities analysts have also issued research reports about the company. Zacks Investment Research raised Dynavax Technologies Corporation from a hold rating to a buy rating and set a $11.00 price objective on the stock in a research note on Monday, July 10th. J P Morgan Chase & Co raised Dynavax Technologies Corporation from a neutral rating to an overweight rating and boosted their price objective for the stock from $6.00 to $27.00 in a research note on Monday, July 31st. Royal Bank Of Canada boosted their price objective on Dynavax Technologies Corporation from $6.00 to $7.00 and gave the stock a sector perform rating in a research note on Tuesday, May 9th. ValuEngine downgraded Dynavax Technologies Corporation from a sell rating to a strong sell rating in a research report on Friday, June 2nd. Finally, William Blair restated an outperform rating on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. Dynavax Technologies Corporation has a consensus rating of Hold and a consensus price target of $23.34.

Dynavax Technologies Corporation (DVAX) traded down 1.22% on Monday, hitting $16.20. 1,419,090 shares of the company’s stock traded hands. Dynavax Technologies Corporation has a 12 month low of $3.20 and a 12 month high of $19.60. The stock’s market cap is $886.90 million. The stock has a 50 day moving average price of $12.61 and a 200-day moving average price of $7.57.

Dynavax Technologies Corporation (NASDAQ:DVAX) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.09. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.15 million. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. During the same period in the previous year, the company posted ($0.75) earnings per share. Equities analysts predict that Dynavax Technologies Corporation will post ($1.58) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first posted by BNB Daily and is the property of of BNB Daily. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.baseball-news-blog.com/2017/08/19/dynavax-technologies-corporation-dvax-downgraded-by-bidaskclub-to-hold-updated-updated.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC boosted its position in Dynavax Technologies Corporation by 54.5% in the second quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 3,700 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its stake in shares of Dynavax Technologies Corporation by 16.5% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 1,700 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in shares of Dynavax Technologies Corporation during the first quarter worth about $121,000. Bank of America Corp DE boosted its stake in shares of Dynavax Technologies Corporation by 2.3% in the first quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 456 shares during the period. Finally, Legal & General Group Plc boosted its stake in shares of Dynavax Technologies Corporation by 18.5% in the second quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 1,950 shares during the period. 57.49% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply